Evidence map›Paper›PMID 37875964›Full record

ArticleFluids and barriers of the CNS2023

SARS-CoV-2 infects epithelial cells of the blood-cerebrospinal fluid barrier rather than endothelial cells or pericytes of the blood-brain barrier.

Chiara Stüdle, Hideaki Nishihara, Sven Wischnewski, Laila Kulsvehagen, Sylvain Perriot, Hiroshi Ishikawa, Horst Schroten, Stephan Frank, Nikolaus Deigendesch, Renaud Du Pasquier and 3 more

Open access · goldAbstract read
In one paragraph

Article in Fluids and barriers of the CNS, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 2 pooled it
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 9 institutions in 3 countries.

Chiara StüdleTheodor Kocher Institute, University of Bern, Bern, Switzerland. chiara.stuedle@unibe.ch.
Hideaki NishiharaTheodor Kocher Institute, University of Bern, Bern, Switzerland.
Sven WischnewskiDepartment of Neurology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Laila KulsvehagenDepartments of Neurology, Biomedicine and Clinical Research, Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel and University of Basel, Basel, Switzerland.
Sylvain PerriotLaboratory of Neuroimmunology, Neuroscience Research Centre, Department of Clinical Neurosciences, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.
Hiroshi IshikawaLaboratory of Clinical Regenerative Medicine, Department of Neurosurgery, University of Tsukuba, Tsukuba, 305-8575, Ibaraki, Japan.
Horst SchrotenPediatric Infectious Diseases, Department of Pediatrics, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Stephan FrankPathology, Institute of Medical Genetics and Pathology, University Hospital Basel and University of Basel, Basel, Switzerland.
Nikolaus DeigendeschPathology, Institute of Medical Genetics and Pathology, University Hospital Basel and University of Basel, Basel, Switzerland.
Renaud Du PasquierLaboratory of Neuroimmunology, Neuroscience Research Centre, Department of Clinical Neurosciences, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.
Lucas SchirmerDepartment of Neurology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Anne-Katrin PröbstelDepartments of Neurology, Biomedicine and Clinical Research, Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel and University of Basel, Basel, Switzerland.
Britta EngelhardtTheodor Kocher Institute, University of Bern, Bern, Switzerland. britta.engelhardt@unibe.ch.
University of Basel · CHUniversity of Bern · CHUniversity of Lausanne · CHBernstein Center for Computational Neuroscience Heidelberg-Mannheim · DEUniversity Hospital Heidelberg · DEUniversity Hospital of Basel · CHUniversity Medical Centre Mannheim · DEUniversity of Tsukuba · JPYamaguchi University · JP

Funding

European Research Council ERC StG "DecOmPress
6 · The paper itself

Abstract

backgroundAs a consequence of SARS-CoV-2 infection various neurocognitive and neuropsychiatric symptoms can appear, which may persist for several months post infection. However, cell type-specific routes of brain infection and underlying mechanisms resulting in neuroglial dysfunction are not well understood.

methodsHere, we investigated the susceptibility of cells constituting the blood-brain barrier (BBB) and the blood-cerebrospinal fluid barrier (BCSFB) of the choroid plexus (ChP) to SARS-CoV-2 infection using human induced pluripotent stem cell (hiPSC)-derived cellular models and a ChP papilloma-derived epithelial cell line as well as ChP tissue from COVID-19 patients, respectively.

resultsWe noted a differential infectibility of hiPSC-derived brain microvascular endothelial cells (BMECs) depending on the differentiation method. Extended endothelial culture method (EECM)-BMECs characterized by a complete set of endothelial markers, good barrier properties and a mature immune phenotype were refractory to SARS-CoV-2 infection and did not exhibit an activated phenotype after prolonged SARS-CoV-2 inoculation. In contrast, defined medium method (DMM)-BMECs, characterized by a mixed endothelial and epithelial phenotype and excellent barrier properties were productively infected by SARS-CoV-2 in an ACE2-dependent manner. hiPSC-derived brain pericyte-like cells (BPLCs) lacking ACE2 expression were not susceptible to SARS-CoV-2 infection. Furthermore, the human choroid plexus papilloma-derived epithelial cell line HIBCPP, modeling the BCSFB was productively infected by SARS-CoV-2 preferentially from the basolateral side, facing the blood compartment. Assessment of ChP tissue from COVID-19 patients by RNA in situ hybridization revealed SARS-CoV-2 transcripts in ChP epithelial and ChP stromal cells.

conclusionsOur study shows that the BCSFB of the ChP rather than the BBB is susceptible to direct SARS-CoV-2 infection. Thus, neuropsychiatric symptoms because of COVID-19 may rather be associated with dysfunction of the BCSFB than the BBB. Future studies should consider a role of the ChP in underlying neuropsychiatric symptoms following SARS-CoV-2 infection.

Indexed as

COVID-19Induced Pluripotent Stem CellsAngiotensin-Converting Enzyme 2Blood-Brain BarrierChoroid PlexusEndothelial CellsEpithelial CellsHumansPericytesSARS-CoV-2Angiotensin-Converting Enzyme 2Blood-brain barrierBlood-cerebrospinal fluid barrierChoroid plexus epithelial cellshiPSC-derived brain microvascular endothelial cellsSARS-CoV-2

Identifiers

PMID37875964
PMCPMC10598911
OpenAlexW4387908010

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.